血必净注射液联合胸腺肽α1治疗慢性肝衰竭的疗效观察

Clinical study on Xuebijing combined with Thymosin αl in treatment of chronic liver failure

目的观察血必净注射液联合胸腺肽α1对慢性肝衰竭患者的疗效。方法将62例慢性肝衰竭的患者随机分成对照组20例、治疗I组21例和治疗Ⅱ组21例。3组均给予保肝、降酶、退黄治疗及抗感染等内科综合治疗。治疗I组加用血必净50 ml/d,疗程2周;治疗Ⅱ组加用血必净50 ml/d,联合胸腺肽α1 1.6 mg,隔天一次,疗程均2周。观察3组患者治疗前后肝功能、中性粒细胞比率、凝血参数、血小板、内毒素水平的变化。结果治疗两周后,治疗Ⅱ组内毒素水平下降和肝功能指标改善与对照组比较差异有显著性(P<0.05与P<0.01),且治疗Ⅱ组疗效优于治疗I组,但治疗Ⅰ、Ⅱ组有效率与对照组比较差异无显著意义(P>0.05)。结论血必净注射液联合胸腺肽a1治疗慢性肝衰竭能明显降低内毒素血症,改善患者的肝功能。

Objective To evaluate the medical effect of Xuebijing combined with thymosin α1 in treatment of patients with chronic liver failure.Methods Sixty two patients were randomly divided into three groups： 20 cases in control group,21 cases in treatment groupⅠand 21 cases in treatment group Ⅱ.Samples of venous blood were collected before and after treatment for determination of blood levels of ALT,TBIL,ALB,PLT,PT,endotoxin and percentage of neutrophils.Results The descending degree of endotoxin level and improvement of liver function in patients of treatment group II after treatment for 2 weeks were greater than those of control group（P0.05 or P0.01）,and the efficacy in treatment group II was better than that of treatment group I.The difference in rate of effectiveness between treatment groupⅠ、Ⅱ and control group was not statistically significant（P0.05）.Conclusion Xuebijing combined with thymosinαl can significantly reduce the level of endotoxin,and it can also improve the liver function of patients with chronic liver failure.